{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:12:10Z","timestamp":1793193130912,"version":"4.5.0"},"reference-count":339,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jconrel.2025.113641","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T04:56:57Z","timestamp":1742446617000},"page":"113641","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Lipid nanoparticle (LNP) mediated mRNA delivery in neurodegenerative diseases"],"prefix":"10.1016","volume":"381","author":[{"given":"Seyedeh Ghazal","family":"Moosavi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloufar","family":"Rahiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Reza","family":"Jaafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Arabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.jconrel.2025.113641_bb0005","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.3390\/molecules25245789","article-title":"Comprehensive review on Alzheimer\u2019s disease: causes and treatment","volume":"25","author":"Breijyeh","year":"2020","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb0010","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41572-021-00280-3","article-title":"Parkinson disease-associated cognitive impairment","volume":"7","author":"Aarsland","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.jconrel.2025.113641_bb0015","first-page":"44","article-title":"Multiple sclerosis: emerging epidemiological trends and redefining the clinical course","author":"Portaccio","year":"2024","journal-title":"Lancet Reg Heal."},{"issue":"7","key":"10.1016\/j.jconrel.2025.113641_bb0020","doi-asserted-by":"crossref","first-page":"20240094","DOI":"10.57197\/JDR-2024-0094","article-title":"Stroke and disability: incidence, risk factors, management, and impact","volume":"3","author":"Jambi","year":"2024","journal-title":"J Disabil Res."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb0025","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/bmb\/ldad010","article-title":"RNA therapeutics for neurological diseases","volume":"147","author":"Brentari","year":"2023","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.jconrel.2025.113641_bb0030","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.3390\/jcm12051709","article-title":"Advances in neurodegenerative diseases","volume":"12","author":"Van Schependom","year":"2023","journal-title":"J. Clini. Med."},{"key":"10.1016\/j.jconrel.2025.113641_bb0035","series-title":"The Neurodegeneration Revolution","first-page":"101","article-title":"Diagnosis and management of neurodegenerative diseases","author":"Kagawad","year":"2025"},{"issue":"11","key":"10.1016\/j.jconrel.2025.113641_bb0040","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMra2215795","article-title":"Messenger RNA translation defects in neurodegenerative diseases","volume":"388","author":"Storkebaum","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.113641_bb0045","series-title":"Nucleic Acid Biology and its Application in Human Diseases","first-page":"105","article-title":"Nucleic acid-based strategies to treat neurodegenerative diseases","author":"Panda","year":"2023"},{"key":"10.1016\/j.jconrel.2025.113641_bb0050","doi-asserted-by":"crossref","first-page":"0056","DOI":"10.34133\/research.0056","article-title":"Restoration of motor function through delayed intraspinal delivery of human IL-10-encoding nucleoside-modified mRNA after spinal cord injury","volume":"6","author":"G\u00e1l","year":"2023","journal-title":"Research"},{"issue":"11","key":"10.1016\/j.jconrel.2025.113641_bb0055","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113641_bb0060","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"issue":"45","key":"10.1016\/j.jconrel.2025.113641_bb0065","doi-asserted-by":"crossref","first-page":"21733","DOI":"10.1039\/C9NR09347H","article-title":"On the role of helper lipids in lipid nanoparticle formulations of siRNA","volume":"11","author":"Kulkarni","year":"2019","journal-title":"Nanoscale"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb0070","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s40824-023-00425-3","article-title":"mRNA nanodelivery systems: targeting strategies and administration routes","volume":"27","author":"Yuan","year":"2023","journal-title":"Biomater Res."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113641_bb0075","doi-asserted-by":"crossref","first-page":"738","DOI":"10.7150\/thno.84291","article-title":"Nanoparticle technology for mRNA: delivery strategy, clinical application and developmental landscape","volume":"14","author":"Li","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2025.113641_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.900610","article-title":"Lipid-based nanoparticles and RNA as innovative neuro-therapeutics","volume":"13","author":"Tsakiri","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.113641_bb0085","article-title":"Gene therapy for CNS disorders: modalities, delivery and translational challenges","volume":"1\u201320","author":"Gao","year":"2024","journal-title":"Nat. Rev. Neurosci."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113641_bb0090","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3390\/pharmaceutics13020206","article-title":"Lipid nanoparticles as delivery systems for RNA-based vaccines","volume":"13","author":"Aldosari","year":"2021","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.jconrel.2025.113641_bb0095","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1089\/nat.2018.0721","article-title":"Lipid nanoparticles enabling gene therapies: from concepts to clinical utility","volume":"28","author":"Kulkarni","year":"2018","journal-title":"Nucleic Acid Ther."},{"issue":"9","key":"10.1016\/j.jconrel.2025.113641_bb0100","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1021\/acs.accounts.9b00368","article-title":"Lipid nanoparticle technology for clinical translation of siRNA therapeutics","volume":"52","author":"Kulkarni","year":"2019","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.jconrel.2025.113641_bb0105","article-title":"Emerging strategies for nanomedicine in autoimmunity","volume":"115194","author":"Thatte","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.113641_bb0110","series-title":"Targeted Therapy to Overcome the Blood-Brain Barrier in Treating Glioblastoma","author":"Belkhodja","year":"2023"},{"issue":"2","key":"10.1016\/j.jconrel.2025.113641_bb0115","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3390\/pharmaceutics12020102","article-title":"Opportunities and challenges in the delivery of mRNA-based vaccines","volume":"12","author":"Wadhwa","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.113641_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.978513","article-title":"Applications of nanobodies in brain diseases","volume":"13","author":"Zheng","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb0125","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12987-023-00462-z","article-title":"Enhanced in vivo blood brain barrier transcytosis of macromolecular cargo using an engineered pH-sensitive mouse transferrin receptor binding nanobody","volume":"20","author":"Esparza","year":"2023","journal-title":"Fluids Barriers CNS."},{"key":"10.1016\/j.jconrel.2025.113641_bb0130","unstructured":"Han EL, Tang S, Kim D, Murray AM, Swingle KL, Hamilton AG, et al. Peptide-functionalized lipid nanoparticles for targeted systemic mRNA delivery to the brain. Nano Lett."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113641_bb0135","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1049\/nbt2.12111","article-title":"The comparison of biodistribution of glutathione PEGylated nanoliposomal doxorubicin formulations prepared by pre-insertion and post-insertion methods for brain delivery in normal mice","volume":"17","author":"Mehrabian","year":"2023","journal-title":"IET Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2025.113641_bb0140","unstructured":"Wang C, Xue Y, Markovic T, Li H, Wang S, Zhong Y, et al. Blood-brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system. Nat. Mater."},{"issue":"7","key":"10.1016\/j.jconrel.2025.113641_bb0145","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3390\/pharmaceutics13071084","article-title":"Focused ultrasound combined with microbubbles in central nervous system applications","volume":"13","author":"Chen","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.113641_bb0150","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2022.05.042","article-title":"Focused ultrasound\/microbubbles-assisted BBB opening enhances LNP-mediated mRNA delivery to brain","volume":"348","author":"Ogawa","year":"2022","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.jconrel.2025.113641_bb0155","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1586\/14737175.2015.1028369","article-title":"Focused ultrasound-mediated drug delivery through the blood\u2013brain barrier","volume":"15","author":"Burgess","year":"2015","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.jconrel.2025.113641_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112048","article-title":"Danhong injection enhances the therapeutic effect of mannitol on hemispheric ischemic stroke by ameliorating blood-brain barrier disruption","volume":"142","author":"Zeng","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jconrel.2025.113641_bb0165","article-title":"A combination of systemic mannitol administration and mannitol-modified polyester nanoparticles facilitate gene delivery to the brain through caveolae-mediated endocytosis","author":"Betsy Reshma","year":"2024","journal-title":"bioRxiv"},{"issue":"3","key":"10.1016\/j.jconrel.2025.113641_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102258","article-title":"Circular RNA-based therapy provides sustained and robust neuroprotection for retinal ganglion cells","volume":"35","author":"Jiang","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2025.113641_bb0175","article-title":"Advances in the design and delivery of RNA vaccines for infectious diseases","volume":"115419","author":"Lokras","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113641_bb0180","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.113641_bb0185","article-title":"Lipid nanoparticles in the development of mRNA vaccines for COVID-19","volume":"74","author":"Wilson","year":"2022","journal-title":"J Drug Deliv Sci Technol."},{"key":"10.1016\/j.jconrel.2025.113641_bb0190","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jconrel.2024.03.056","article-title":"mRNA therapies: pioneering a new era in rare genetic disease treatment","volume":"369","author":"Shen","year":"2024","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb0195","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","article-title":"Chemistry of lipid nanoparticles for RNA delivery","volume":"55","author":"Eygeris","year":"2021","journal-title":"Acc. Chem. Res."},{"issue":"11","key":"10.1016\/j.jconrel.2025.113641_bb0200","doi-asserted-by":"crossref","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid nanoparticles from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2025.113641_bb0205","first-page":"86","article-title":"Engineering LNPs with polysarcosine lipids for mRNA delivery","volume":"37","author":"Kang","year":"2024","journal-title":"Bioact Mater."},{"issue":"11","key":"10.1016\/j.jconrel.2025.113641_bb0210","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2307800120","article-title":"Endosomal escape: a bottleneck for LNP-mediated therapeutics","volume":"121","author":"Chatterjee","year":"2024","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2025.113641_bb0215","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jconrel.2024.06.023","article-title":"Lipid nanoparticle (LNP) mediated mRNA delivery in cardiovascular diseases: advances in genome editing and CAR T cell therapy","volume":"372","author":"Soroudi","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113641_bb0220","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Albertsen","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb0225","doi-asserted-by":"crossref","first-page":"7233","DOI":"10.1038\/s41467-021-27493-0","article-title":"An ionizable lipid toolbox for RNA delivery","volume":"12","author":"Han","year":"2021","journal-title":"Nat. Commun."},{"issue":"17","key":"10.1016\/j.jconrel.2025.113641_bb0230","doi-asserted-by":"crossref","first-page":"2206968","DOI":"10.1002\/smll.202206968","article-title":"Biodegradable cationic and ionizable cationic lipids: a roadmap for safer pharmaceutical excipients","volume":"19","author":"J\u00f6rgensen","year":"2023","journal-title":"Small"},{"issue":"2","key":"10.1016\/j.jconrel.2025.113641_bb0235","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nbt.1602","article-title":"Rational design of cationic lipids for siRNA delivery","volume":"28","author":"Semple","year":"2010","journal-title":"Nat. Biotechnol."},{"issue":"9","key":"10.1016\/j.jconrel.2025.113641_bb0240","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1039\/D1NA00712B","article-title":"Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing","volume":"4","author":"Sarode","year":"2022","journal-title":"Nanoscale Adv."},{"issue":"12","key":"10.1016\/j.jconrel.2025.113641_bb0245","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"issue":"6","key":"10.1016\/j.jconrel.2025.113641_bb0250","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1021\/acs.molpharmaceut.1c00916","article-title":"Lipid-nanoparticle-based delivery of CRISPR\/Cas9 genome-editing components","volume":"19","author":"Kazemian","year":"2022","journal-title":"Mol. Pharm."},{"issue":"15","key":"10.1016\/j.jconrel.2025.113641_bb0255","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/sj.gt.3301506","article-title":"On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids","volume":"8","author":"Hafez","year":"2001","journal-title":"Gene Ther."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113641_bb0260","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2025.113641_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.chemphyslip.2020.105032","article-title":"Cationic lipids for gene delivery: many players, one goal","volume":"235","author":"Ponti","year":"2021","journal-title":"Chem. Phys. Lipids"},{"issue":"34","key":"10.1016\/j.jconrel.2025.113641_bb0270","doi-asserted-by":"crossref","first-page":"8657","DOI":"10.1002\/ange.201203263","article-title":"Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo","volume":"124","author":"Jayaraman","year":"2012","journal-title":"Angew. Chem."},{"issue":"6","key":"10.1016\/j.jconrel.2025.113641_bb0275","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","article-title":"A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates","volume":"26","author":"Sabnis","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2025.113641_bb0280","article-title":"Increased FAN1 expression by mRNA-LNP attenuates CAG repeat expansion in Huntington patients\u2019 iPSC-derived astrocytes","author":"Cheng","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.jconrel.2025.113641_bb0285","doi-asserted-by":"crossref","first-page":"12181","DOI":"10.1021\/acs.chemrev.1c00244","article-title":"Lipids and Lipid Derivatives for RNA Delivery","volume":"121","author":"Zhang","year":"2021","journal-title":"Chem. Rev."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113641_bb0290","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jconrel.2005.06.014","article-title":"Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids","volume":"107","author":"Heyes","year":"2005","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb0295","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb0300","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11095-022-03460-2","article-title":"Structure and function of cationic and ionizable lipids for nucleic acid delivery","volume":"40","author":"Sun","year":"2023","journal-title":"Pharm. Res."},{"issue":"6","key":"10.1016\/j.jconrel.2025.113641_bb0305","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.tips.2021.03.002","article-title":"The importance of apparent pKa in the development of nanoparticles encapsulating siRNA and mRNA","volume":"42","author":"Patel","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2025.113641_bb0310","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.addr.2020.06.002","article-title":"Lipid nanoparticles for nucleic acid delivery: current perspectives","volume":"154","author":"Samaridou","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"10","key":"10.1016\/j.jconrel.2025.113641_bb0315","doi-asserted-by":"crossref","first-page":"6449","DOI":"10.1021\/acs.nanolett.8b02917","article-title":"Optimization of a degradable polymer\u2013lipid nanoparticle for potent systemic delivery of mRNA to the lung endothelium and immune cells","volume":"18","author":"Kaczmarek","year":"2018","journal-title":"Nano Lett."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb0320","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41467-020-14527-2","article-title":"Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA","volume":"11","author":"Patel","year":"2020","journal-title":"Nat. Commun."},{"issue":"15","key":"10.1016\/j.jconrel.2025.113641_bb0325","doi-asserted-by":"crossref","first-page":"E3351","DOI":"10.1073\/pnas.1720542115","article-title":"Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles","volume":"115","author":"Yanez Arteta","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113641_bb0330","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.1021\/acsnano.8b01516","article-title":"On the formation and morphology of lipid nanoparticles containing ionizable cationic lipids and siRNA","volume":"12","author":"Kulkarni","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2025.113641_bb0335","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.addr.2016.01.022","article-title":"The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery","volume":"99","author":"Cheng","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113641_bb0340","doi-asserted-by":"crossref","first-page":"492","DOI":"10.2174\/1567201813666160712164149","article-title":"Stimulation of tumor-specific immunity by p5 HER-2\/neu generated peptide encapsulated in Nano-liposomes with high phase transition temperature phospholipids","volume":"14","author":"Yazdani","year":"2017","journal-title":"Curr. Drug Deliv."},{"issue":"9","key":"10.1016\/j.jconrel.2025.113641_bb0345","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1039\/D3BM00068K","article-title":"Increasing the siRNA knockdown efficiency of lipid nanoparticles by morphological transformation with the use of dihydrosphingomyelin as a helper lipid","volume":"11","author":"Hashimoto","year":"2023","journal-title":"Biomater. Sci."},{"issue":"11","key":"10.1016\/j.jconrel.2025.113641_bb0350","doi-asserted-by":"crossref","first-page":"5164","DOI":"10.1039\/C4NJ01314J","article-title":"Cationic liposome\u2013nucleic acid complexes for gene delivery and gene silencing","volume":"38","author":"Safinya","year":"2014","journal-title":"New J. Chem."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb0355","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0168-3659(02)00167-0","article-title":"Characterization of a novel diolein-based LPDII vector for gene delivery","volume":"83","author":"Guo","year":"2002","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2025.113641_bb0360","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1021\/mp200426h","article-title":"SPANosomes as delivery vehicles for small interfering RNA (siRNA)","volume":"9","author":"Zhou","year":"2012","journal-title":"Mol. Pharm."},{"issue":"11","key":"10.1016\/j.jconrel.2025.113641_bb0365","doi-asserted-by":"crossref","first-page":"2300123","DOI":"10.1002\/biot.202300123","article-title":"Exploration of mRNA nanoparticles based on DOTAP through optimization of the helper lipids","volume":"18","author":"Ma","year":"2023","journal-title":"Biotechnol. J."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb0370","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ijpharm.2014.04.056","article-title":"Recent development of poly (ethylene glycol)-cholesterol conjugates as drug delivery systems","volume":"469","author":"He","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.113641_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119792","article-title":"PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: faster PEG shedding attenuates anti-PEG IgM production","volume":"588","author":"Suzuki","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.113641_bb0380","first-page":"3","article-title":"Shielding of lipid nanoparticles for siRNA delivery: impact on physicochemical properties, cytokine induction, and efficacy","author":"Kumar","year":"2014","journal-title":"Mol Ther-Nucleic Acids"},{"issue":"2","key":"10.1016\/j.jconrel.2025.113641_bb0385","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2174\/0929867043456179","article-title":"Self-assembling nucleic acid delivery vehicles via linear, water-soluble, cyclodextrin-containing polymers","volume":"11","author":"Davis","year":"2004","journal-title":"Curr. Med. Chem."},{"issue":"14","key":"10.1016\/j.jconrel.2025.113641_bb0390","doi-asserted-by":"crossref","first-page":"1606628","DOI":"10.1002\/adma.201606628","article-title":"Rational design of cancer nanomedicine: nanoproperty integration and synchronization","volume":"29","author":"Sun","year":"2017","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2025.113641_bb0395","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jconrel.2022.09.002","article-title":"Stealth nanoparticles in oncology: facing the PEG dilemma","volume":"351","author":"Zalba","year":"2022","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb0400","doi-asserted-by":"crossref","first-page":"16744","DOI":"10.1038\/s41598-023-43898-x","article-title":"Elucidation of lipid nanoparticle surface structure in mRNA vaccines","volume":"13","author":"Wang","year":"2023","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb0405","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ijpharm.2013.07.059","article-title":"Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration","volume":"456","author":"Lila","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.113641_bb0410","doi-asserted-by":"crossref","unstructured":"Maruyama K, Okuizumi S, Ishida O, Yamauchi H, Kikuchi H, Iwatsuru M. Phosphatidyl polyglycerols prolong liposome circulation in vivo. Int. J. Pharm. 1994;111(1):103\u20137.","DOI":"10.1016\/0378-5173(94)90407-3"},{"issue":"8","key":"10.1016\/j.jconrel.2025.113641_bb0415","doi-asserted-by":"crossref","first-page":"2302712","DOI":"10.1002\/adhm.202302712","article-title":"Poly (N-methyl-N-vinylacetamide): a strong alternative to PEG for lipid-based nanocarriers delivering siRNA","volume":"13","author":"Berger","year":"2024","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2025.113641_bb0420","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.biomaterials.2018.05.022","article-title":"Poly (2-oxazoline) s based biomaterials: a comprehensive and critical update","volume":"178","author":"Lorson","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.113641_bb0425","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jconrel.2020.04.011","article-title":"Hepatosplenic phagocytic cells indirectly contribute to anti-PEG IgM production in the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes: appearance of an unexplained mechanism in the ABC phenomenon","volume":"323","author":"El Sayed","year":"2020","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.jconrel.2025.113641_bb0430","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1021\/acs.bioconjchem.3c00174","article-title":"PEGylated lipid nanoparticle formulations: immunological safety and efficiency perspective","volume":"34","author":"Tenchov","year":"2023","journal-title":"Bioconjug. Chem."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113641_bb0435","doi-asserted-by":"crossref","first-page":"2100109","DOI":"10.1002\/anbr.202100109","article-title":"Lipid nanoparticles for drug delivery","volume":"2","author":"Xu","year":"2022","journal-title":"Adv NanoBiomed Res."},{"issue":"28","key":"10.1016\/j.jconrel.2025.113641_bb0440","doi-asserted-by":"crossref","first-page":"8698","DOI":"10.1021\/acs.jpcb.5b02891","article-title":"Microfluidic mixing: a general method for encapsulating macromolecules in lipid nanoparticle systems","volume":"119","author":"Leung","year":"2015","journal-title":"J. Phys. Chem. B"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb0445","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41392-022-01298-z","article-title":"Nucleic acid drug vectors for diagnosis and treatment of brain diseases","volume":"8","author":"Lu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113641_bb0450","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","article-title":"Delivering the messenger: advances in technologies for therapeutic mRNA delivery","volume":"27","author":"Kowalski","year":"2019","journal-title":"Mol. Ther."},{"issue":"8","key":"10.1016\/j.jconrel.2025.113641_bb0455","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/nbt.3298","article-title":"Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown","volume":"33","author":"Wittrup","year":"2015","journal-title":"Nat. Biotechnol."},{"issue":"8","key":"10.1016\/j.jconrel.2025.113641_bb0460","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002597","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer","volume":"9","author":"Emens","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"11\u221212","key":"10.1016\/j.jconrel.2025.113641_bb0465","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1101\/gad.350752.123","article-title":"Translational regulation by uORFs and start codon selection stringency","volume":"37","author":"Dever","year":"2023","journal-title":"Genes Dev."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113641_bb0470","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/wrna.56","article-title":"Control of poly (a) tail length","volume":"2","author":"Eckmann","year":"2011","journal-title":"Wiley Interdiscip Rev RNA."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113641_bb0475","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.3390\/ijms24032700","article-title":"A comprehensive review of mRNA vaccines","volume":"24","author":"Gote","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"22","key":"10.1016\/j.jconrel.2025.113641_bb0480","doi-asserted-by":"crossref","first-page":"10898","DOI":"10.1093\/nar\/gkw671","article-title":"Role of mRNA structure in the control of protein folding","volume":"44","author":"Faure","year":"2016","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb0485","article-title":"Balance dysfunction in Parkinson\u2019s disease","volume":"2015","author":"Rinalduzzi","year":"2015","journal-title":"Biomed. Res. Int."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113641_bb0490","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1176\/jnp.14.2.223","article-title":"An essay on the shaking palsy","volume":"14","author":"Parkinson","year":"2002","journal-title":"J. Neuropsychiatr. Clin. Neurosci."},{"issue":"10","key":"10.1016\/j.jconrel.2025.113641_bb0495","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/s41593-018-0221-2","article-title":"Selective vulnerability in neurodegenerative diseases","volume":"21","author":"Fu","year":"2018","journal-title":"Nat. Neurosci."},{"issue":"s1","key":"10.1016\/j.jconrel.2025.113641_bb0500","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.3233\/JPD-181493","article-title":"The search for environmental causes of Parkinson\u2019s disease: moving forward","volume":"8","author":"Chen","year":"2018","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.jconrel.2025.113641_bb0505","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1016\/j.jalz.2014.04.014","article-title":"The disease intersection of susceptibility and exposure: chemical exposures and neurodegenerative disease risk","volume":"10","author":"Tanner","year":"2014","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jconrel.2025.113641_bb0510","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"Poewe","year":"2017","journal-title":"Parkinson Dis. Nat. Rev. Dis. Primers"},{"issue":"2","key":"10.1016\/j.jconrel.2025.113641_bb0515","article-title":"Targeting the pathogenesis and boosting the therapeutic efficacy of Parkinson\u2019s disease by advanced nanoparticles","volume":"2","author":"Liu","year":"2023","journal-title":"MedComm\u2013Biomaterials Appl."},{"issue":"9","key":"10.1016\/j.jconrel.2025.113641_bb0520","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1093\/brain\/awad150","article-title":"Advances in understanding the function of alpha-synuclein: implications for Parkinson\u2019s disease","volume":"146","author":"Calabresi","year":"2023","journal-title":"Brain"},{"issue":"13","key":"10.1016\/j.jconrel.2025.113641_bb0525","doi-asserted-by":"crossref","first-page":"11022","DOI":"10.3390\/ijms241311022","article-title":"Are therapies that target \u03b1-synuclein effective at halting Parkinson\u2019s disease progression? A systematic review","volume":"24","author":"Rodger","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113641_bb0530","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s13311-019-00714-7","article-title":"Nucleic acid\u2013based therapeutics for Parkinson\u2019s disease","volume":"16","author":"Nakamori","year":"2019","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jconrel.2025.113641_bb0535","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.coph.2015.10.006","article-title":"Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson\u2019s disease","volume":"26","author":"Olson","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb0540","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/s41467-020-15626-w","article-title":"\u03b1-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson\u2019s disease","volume":"11","author":"Lindestam Arlehamn","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.113641_bb0545","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-021-02296-8","article-title":"T-cell dysregulation is associated with disease severity in Parkinson\u2019s disease","volume":"18","author":"Bhatia","year":"2021","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jconrel.2025.113641_bb0550","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.bbi.2022.10.023","article-title":"\u03b1-Synuclein induces Th17 differentiation and impairs the function and stability of Tregs by promoting RORC transcription in Parkinson\u2019s disease","volume":"108","author":"Li","year":"2023","journal-title":"Brain Behav. Immun."},{"issue":"8","key":"10.1016\/j.jconrel.2025.113641_bb0555","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.parkreldis.2005.07.005","article-title":"Alterations of T-lymphocyte populations in Parkinson disease","volume":"11","author":"Baba","year":"2005","journal-title":"Parkinsonism Relat. Disord."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113641_bb0560","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1212\/CON.0000000000000764","article-title":"Parkinson disease","volume":"25","author":"Zesiewicz","year":"2019","journal-title":"Contin Lifelong Learn Neurol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb0565","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.14108","article-title":"Parkinson disease","volume":"27","author":"Balestrino","year":"2020","journal-title":"Eur. J. Neurol."},{"issue":"6","key":"10.1016\/j.jconrel.2025.113641_bb0570","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/mds.23732","article-title":"Etiology and pathogenesis of Parkinson\u2019s disease","volume":"26","author":"Schapira","year":"2011","journal-title":"Mov. Disord."},{"issue":"16","key":"10.1016\/j.jconrel.2025.113641_bb0575","doi-asserted-by":"crossref","first-page":"9361","DOI":"10.3390\/ijms23169361","article-title":"Lipid nanoparticles: promising treatment approach for Parkinson\u2019s disease","volume":"23","author":"Jagaran","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2025.113641_bb0580","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1590\/0004-282x-anp-2020-0507","article-title":"Assessment of therapeutic strategies for management of impulse control disorder in Parkinson\u2019s disease","volume":"79","author":"Rodr\u00edguez-Violante","year":"2021","journal-title":"Arq. Neuropsiquiatr."},{"issue":"16","key":"10.1016\/j.jconrel.2025.113641_bb0585","doi-asserted-by":"crossref","first-page":"9082","DOI":"10.3390\/ijms22169082","article-title":"Nanomedicine for neurodegenerative disorders: focus on Alzheimer\u2019s and Parkinson\u2019s diseases","volume":"22","author":"Jagaran","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.jconrel.2025.113641_bb0590","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/mds.22686","article-title":"Pallidal stimulation for segmental dystonia: long term follow up of 11 consecutive patients","volume":"24","author":"Sensi","year":"2009","journal-title":"Mov. Disord."},{"issue":"24","key":"10.1016\/j.jconrel.2025.113641_bb0595","doi-asserted-by":"crossref","first-page":"e2238","DOI":"10.1212\/WNL.0000000000006643","article-title":"Levodopa-induced dyskinesia in Parkinson disease: a population-based cohort study","volume":"91","author":"Turcano","year":"2018","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jconrel.2025.113641_bb0600","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of Parkinson disease: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2025.113641_bb0605","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/bs.irn.2017.09.003","article-title":"Nanoformulation: a useful therapeutic strategy for improving neuroprotection and the neurorestorative potential in experimental models of Parkinson\u2019s disease","volume":"137","author":"Lafuente","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.jconrel.2025.113641_bb0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120786","article-title":"Granulocyte-macrophage colony-stimulating factor mRNA and neuroprotective immunity in Parkinson\u2019s disease","volume":"272","author":"Olson","year":"2021","journal-title":"Biomaterials"},{"issue":"8","key":"10.1016\/j.jconrel.2025.113641_bb0615","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1089\/jir.2014.0149","article-title":"Dual role of GM-CSF as a pro-inflammatory and a regulatory cytokine: implications for immune therapy","volume":"35","author":"Bhattacharya","year":"2015","journal-title":"J. Interf. Cytokine Res."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2025.113641_bb0620","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2013.10.009","article-title":"GM-CSF induces neuroprotective and anti-inflammatory responses in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine intoxicated mice","volume":"265","author":"Kosloski","year":"2013","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jconrel.2025.113641_bb0625","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jconrel.2022.06.024","article-title":"Development of an extended half-life GM-CSF fusion protein for Parkinson\u2019s disease","volume":"348","author":"Yeapuri","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113641_bb0630","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jconrel.2022.02.009","article-title":"Recent advancements in nanoparticle-mediated approaches for restoration of multiple sclerosis","volume":"343","author":"Rahiman","year":"2022","journal-title":"J. Control. Release"},{"issue":"11","key":"10.1016\/j.jconrel.2025.113641_bb0635","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1212\/WNL.0000000000002469","article-title":"Multiple sclerosis prevalence in the United States commercially insured population","volume":"86","author":"Dilokthornsakul","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jconrel.2025.113641_bb0640","first-page":"3","article-title":"The genetics of multiple sclerosis","author":"Didonna","year":"2017","journal-title":"Exon. Publ."},{"key":"10.1016\/j.jconrel.2025.113641_bb0645","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.600428","article-title":"Immunosuppressive amino-acid catabolizing enzymes in multiple sclerosis","volume":"11","author":"Correale","year":"2021","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.jconrel.2025.113641_bb0650","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1172\/JCI29251","article-title":"Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis","volume":"116","author":"Astier","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113641_bb0655","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-3083.1995.tb03550.x","article-title":"Increased mRNA expression of IL-10 in mononuclear cells in multiple sclerosis and optic neuritis","volume":"41","author":"Navikas","year":"1995","journal-title":"Scand. J. Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb0660","article-title":"An overview of the history, pathophysiology, and pharmacological interventions of multiple sclerosis","volume":"15","author":"Dighriri","year":"2023","journal-title":"Cureus"},{"issue":"12","key":"10.1016\/j.jconrel.2025.113641_bb0665","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1080\/17425247.2021.2003327","article-title":"An insight into the role of liposomal therapeutics in the reversion of multiple sclerosis","volume":"18","author":"Rahiman","year":"2021","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2025.113641_bb0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123620","article-title":"Novel liposomal glatiramer acetate: preparation and immunomodulatory evaluation in murine model of multiple sclerosis","volume":"648","author":"Rahiman","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.113641_bb0675","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.omtn.2022.04.012","article-title":"Intermittent lipid nanoparticle mRNA administration prevents cortical dysmyelination associated with arginase deficiency","volume":"28","author":"Khoja","year":"2022","journal-title":"Mol Ther-Nucleic Acids"},{"issue":"12","key":"10.1016\/j.jconrel.2025.113641_bb0680","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/s41591-018-0199-z","article-title":"Systemic messenger RNA as an etiological treatment for acute intermittent porphyria","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.jconrel.2025.113641_bb0685","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.3390\/ph16091270","article-title":"Tolerogenic lipid nanoparticles for delivering self-antigen mRNA for the treatment of experimental autoimmune encephalomyelitis","volume":"16","author":"Gomi","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jconrel.2025.113641_bb0690","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jconrel.2018.10.028","article-title":"Anionic 1, 2-distearoyl-sn-glycero-3-phosphoglycerol (DSPG) liposomes induce antigen-specific regulatory T cells and prevent atherosclerosis in mice","volume":"291","author":"Benne","year":"2018","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.jconrel.2025.113641_bb0695","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/ni0411-283","article-title":"Maturation of effector regulatory T cells","volume":"12","author":"Ohkura","year":"2011","journal-title":"Nat. Immunol."},{"issue":"22","key":"10.1016\/j.jconrel.2025.113641_bb0700","doi-asserted-by":"crossref","first-page":"10179","DOI":"10.1021\/acs.nanolett.3c02573","article-title":"mRNA lipid nanoparticles for ex vivo engineering of immunosuppressive T cells for autoimmunity therapies","volume":"23","author":"Thatte","year":"2023","journal-title":"Nano Lett."},{"issue":"33","key":"10.1016\/j.jconrel.2025.113641_bb0705","doi-asserted-by":"crossref","first-page":"1606944","DOI":"10.1002\/adma.201606944","article-title":"Synthesis and biological evaluation of ionizable lipid materials for the in vivo delivery of messenger RNA to B lymphocytes","volume":"29","author":"Fenton","year":"2017","journal-title":"Adv. Mater."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113641_bb0710","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1179\/1079026814Z.000000000260","article-title":"Spinal cord injury facts and figures at a glance","volume":"37","author":"Center","year":"2014","journal-title":"J. Spinal Cord Med."},{"key":"10.1016\/j.jconrel.2025.113641_bb0715","doi-asserted-by":"crossref","first-page":"1490855","DOI":"10.3389\/fmicb.2024.1490855","article-title":"Spinal cord injury: pathophysiology, possible treatments and the role of the gut microbiota","volume":"15","author":"Pagan-Rivera","year":"2024","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.jconrel.2025.113641_bb0720","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10143-018-1008-3","article-title":"Recent update on basic mechanisms of spinal cord injury","volume":"43","author":"Quadri","year":"2020","journal-title":"Neurosurg. Rev."},{"issue":"8","key":"10.1016\/j.jconrel.2025.113641_bb0725","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/nrn1956","article-title":"Glial inhibition of CNS axon regeneration","volume":"7","author":"Yiu","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.jconrel.2025.113641_bb0730","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/B978-0-444-52137-8.00030-9","article-title":"Harmful and beneficial effects of inflammation after spinal cord injury: potential therapeutic implications","volume":"109","author":"David","year":"2012","journal-title":"Handb. Clin. Neurol."},{"issue":"7","key":"10.1016\/j.jconrel.2025.113641_bb0735","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.ymthe.2018.04.022","article-title":"Local immunomodulation with anti-inflammatory cytokine-encoding lentivirus enhances functional recovery after spinal cord injury","volume":"26","author":"Park","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2025.113641_bb0740","first-page":"6","article-title":"The M1 and M2 paradigm of macrophage activation: time for reassessment","author":"Martinez","year":"2014","journal-title":"F1000prime Rep."},{"issue":"7","key":"10.1016\/j.jconrel.2025.113641_bb0745","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/nrn3053","article-title":"Repertoire of microglial and macrophage responses after spinal cord injury","volume":"12","author":"David","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"issue":"15","key":"10.1016\/j.jconrel.2025.113641_bb0750","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1089\/neu.2012.2651","article-title":"The therapeutic role of interleukin-10 after spinal cord injury","volume":"30","author":"Thompson","year":"2013","journal-title":"J. Neurotrauma"},{"issue":"11\u201312","key":"10.1016\/j.jconrel.2025.113641_bb0755","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1089\/ten.tea.2019.0321","article-title":"Polycistronic delivery of IL-10 and NT-3 promotes oligodendrocyte myelination and functional recovery in a mouse spinal cord injury model","volume":"26","author":"Smith","year":"2020","journal-title":"Tissue Eng. Part A"},{"key":"10.1016\/j.jconrel.2025.113641_bb0760","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.omtn.2019.06.016","article-title":"Enhancement of motor function recovery after spinal cord injury in mice by delivery of brain-derived neurotrophic factor mRNA","volume":"17","author":"Crowley","year":"2019","journal-title":"Mol Ther-Nucleic Acids"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb0765","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4103\/1673-5374.344830","article-title":"Molecular approaches for spinal cord injury treatment","volume":"18","author":"de Almeida","year":"2023","journal-title":"Neural Regen. Res."},{"issue":"01","key":"10.1016\/j.jconrel.2025.113641_bb0770","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.cjtee.2022.04.007","article-title":"Clinical characteristics and treatment of spinal cord injury in children and adolescents","volume":"26","author":"Wang","year":"2023","journal-title":"Chin. J. Traumatol."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113641_bb0775","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.bbadis.2011.10.017","article-title":"Antioxidant therapies in traumatic brain and spinal cord injury","volume":"1822","author":"Bains","year":"2012","journal-title":"Biochim Biophys Acta BBA-Mol Basis Dis."},{"key":"10.1016\/j.jconrel.2025.113641_bb0780","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12868-018-0460-x","article-title":"Anti-inflammatory effects of minocycline are mediated by retinoid signaling","volume":"19","author":"Clemens","year":"2018","journal-title":"BMC Neurosci."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb0785","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.expneurol.2009.08.018","article-title":"IL-10 promotes neuronal survival following spinal cord injury","volume":"220","author":"Zhou","year":"2009","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.jconrel.2025.113641_bb0790","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.1016\/j.ibneur.2023.08.260","article-title":"Delayed INTRASPINAL delivery of MRNAS encoding a combination of cytokines and GDNF promotes morphological and functional recovery following spinal cord injury","volume":"15","author":"G\u00e1l","year":"2023","journal-title":"IBRO Neurosci Rep."},{"key":"10.1016\/j.jconrel.2025.113641_bb0795","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.actbio.2023.12.009","article-title":"Oligodendrocyte progenitor cell-specific delivery of lipid nanoparticles loaded with Olig2 synthetically modified messenger RNA for ischemic stroke therapy","volume":"174","author":"Xu","year":"2024","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2025.113641_bb0800","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jconrel.2023.12.020","article-title":"Selective homing of brain-derived reconstituted lipid nanoparticles to cerebral ischemic area enables improved ischemic stroke treatment","volume":"365","author":"Han","year":"2024","journal-title":"J. Control. Release"},{"issue":"10","key":"10.1016\/j.jconrel.2025.113641_bb0805","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJM200009073431007","article-title":"Treatment of acute ischemic stroke","volume":"343","author":"Brott","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113641_bb0810","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1021\/acsnano.3c09817","article-title":"Targeted mRNA Nanoparticles Ameliorate Blood\u2013Brain Barrier Disruption Postischemic Stroke by Modulating Microglia Polarization","volume":"18","author":"Gao","year":"2024","journal-title":"ACS Nano"},{"issue":"20","key":"10.1016\/j.jconrel.2025.113641_bb0815","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.3390\/molecules27207080","article-title":"Mechanism and regulation of microglia polarization in intracerebral hemorrhage","volume":"27","author":"Guo","year":"2022","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb0820","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jconrel.2012.05.041","article-title":"PEGylation of interleukin-10 improves the pharmacokinetic profile and enhances the antifibrotic effectivity in CCl4-induced fibrogenesis in mice","volume":"162","author":"Mattos","year":"2012","journal-title":"J. Control. Release"},{"issue":"12","key":"10.1016\/j.jconrel.2025.113641_bb0825","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1016\/j.celrep.2017.11.081","article-title":"Systemic messenger RNA therapy as a treatment for methylmalonic acidemia","volume":"21","author":"An","year":"2017","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113641_bb0830","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1159\/000525822","article-title":"Treatments in ischemic stroke: current and future","volume":"85","author":"Mosconi","year":"2022","journal-title":"Eur. Neurol."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113641_bb0835","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.ymthe.2024.03.004","article-title":"Targeting lipid nanoparticles to the blood-brain barrier to ameliorate acute ischemic stroke","volume":"32","author":"Nong","year":"2024","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113641_bb0840","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113641_bb0845","first-page":"129","article-title":"Huntington disease: mechanism of pathogenesis and recent developments in its therapeutic strategies: a review","volume":"5","author":"Eje","year":"2023","journal-title":"J. Chem Rev."},{"key":"10.1016\/j.jconrel.2025.113641_bb0850","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ajmg.b.30992","article-title":"CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches","volume":"153","author":"Langbehn","year":"2010","journal-title":"Am J Med Genet B Neuropsychiatr Genet B."},{"issue":"6","key":"10.1016\/j.jconrel.2025.113641_bb0855","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes","volume":"72","author":"MacDonald","year":"1993","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.jconrel.2025.113641_bb0860","first-page":"293","article-title":"Huntington disease update: new insights into the role of repeat instability in disease pathogenesis","volume":"33","author":"Arning","year":"2022","journal-title":"Med. Genet."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb0865","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3233\/JHD-200445","article-title":"What is the pathogenic CAG expansion length in Huntington\u2019s disease?","volume":"10","author":"Donaldson","year":"2021","journal-title":"J Huntingt Dis."},{"issue":"12","key":"10.1016\/j.jconrel.2025.113641_bb0870","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1136\/jmg.30.12.982","article-title":"Gametic but not somatic instability of CAG repeat length in Huntington\u2019s disease","volume":"30","author":"MacDonald","year":"1993","journal-title":"J. Med. Genet."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb0875","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3233\/JHD-200448","article-title":"FAN1, a DNA repair nuclease, as a modifier of repeat expansion disorders","volume":"10","author":"Deshmukh","year":"2021","journal-title":"J Huntingt Dis."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113641_bb0880","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/jmg.3.4.298","article-title":"Huntington\u2019s chorea","volume":"3","author":"Myrianthopoulos","year":"1966","journal-title":"J. Med. Genet."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113641_bb0885","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2954","article-title":"Mental health symptoms among those affected by Huntington\u2019s disease: a cross-sectional study","volume":"13","author":"Gunn","year":"2023","journal-title":"Brain Behav."},{"issue":"19","key":"10.1016\/j.jconrel.2025.113641_bb0890","doi-asserted-by":"crossref","first-page":"e2395","DOI":"10.1212\/WNL.0000000000011893","article-title":"Timing and impact of psychiatric, cognitive, and motor abnormalities in Huntington disease","volume":"96","author":"McAllister","year":"2021","journal-title":"Neurology"},{"issue":"16","key":"10.1016\/j.jconrel.2025.113641_bb0895","doi-asserted-by":"crossref","first-page":"8363","DOI":"10.3390\/ijms22168363","article-title":"New avenues for the treatment of Huntington\u2019s disease","volume":"22","author":"Kim","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113641_bb0900","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2217\/fnl-2017-0035","article-title":"New directions in therapeutics for Huntington disease","volume":"13","author":"Potkin","year":"2018","journal-title":"Future Neurol."},{"issue":"6","key":"10.1016\/j.jconrel.2025.113641_bb0905","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1212\/WNL.0b013e318263c443","article-title":"Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology","volume":"79","author":"Armstrong","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jconrel.2025.113641_bb0910","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11910-017-0739-9","article-title":"Huntington\u2019s disease\u2014update on treatments","volume":"17","author":"Wyant","year":"2017","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.jconrel.2025.113641_bb0915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-020-01475-9","article-title":"Onset features and time to diagnosis in Friedreich\u2019s Ataxia","volume":"15","author":"Indelicato","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113641_bb0920","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.29687","article-title":"Predictors of survival in Friedreich\u2019s Ataxia: a prospective cohort study","volume":"39","author":"Indelicato","year":"2024","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb0925","doi-asserted-by":"crossref","first-page":"20019","DOI":"10.1038\/srep20019","article-title":"Intrathecal delivery of frataxin mRNA encapsulated in lipid nanoparticles to dorsal root ganglia as a potential therapeutic for Friedreich\u2019s ataxia","volume":"6","author":"Nabhan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2025.113641_bb0930","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/jnc.12322","article-title":"Co-enzyme Q10 and idebenone use in Friedreich\u2019s ataxia","volume":"126","author":"Parkinson","year":"2013","journal-title":"J. Neurochem."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113641_bb0935","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/ana.1001","article-title":"Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich\u2019s ataxia","volume":"49","author":"Lodi","year":"2001","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb0940","doi-asserted-by":"crossref","first-page":"12583","DOI":"10.1038\/srep12583","article-title":"Molecular mechanisms of the non-coenzyme action of thiamin in brain: biochemical, structural and pathway analysis","volume":"5","author":"Mkrtchyan","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2025.113641_bb0945","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/jnc.12300","article-title":"Deferiprone for the treatment of Friedreich\u2019s ataxia","volume":"126","author":"Pandolfo","year":"2013","journal-title":"J. Neurochem."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113641_bb0950","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pjnns.2018.02.003","article-title":"Progress in the treatment of Friedreich ataxia","volume":"52","author":"Tai","year":"2018","journal-title":"Neurol. Neurochir. Pol."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113641_bb0955","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.3390\/ijms22041815","article-title":"Future prospects of gene therapy for Friedreich\u2019s ataxia","volume":"22","author":"Ocana-Santero","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.jconrel.2025.113641_bb0960","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3390\/vaccines12060659","article-title":"mRNA vaccine for Alzheimer\u2019s disease: pilot study","volume":"12","author":"Hovakimyan","year":"2024","journal-title":"Vaccines"},{"issue":"10284","key":"10.1016\/j.jconrel.2025.113641_bb0965","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer\u2019s disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jconrel.2025.113641_bb0970","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","article-title":"Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Nat. Rev. Neurol."},{"issue":"10","key":"10.1016\/j.jconrel.2025.113641_bb0975","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","article-title":"The amyloid-\u03b2 pathway in Alzheimer\u2019s disease","volume":"26","author":"Hampel","year":"2021","journal-title":"Mol. Psychiatry"},{"issue":"4","key":"10.1016\/j.jconrel.2025.113641_bb0980","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1110\/ps.062514807","article-title":"Role of aggregation conditions in structure, stability, and toxicity of intermediates in the A\u03b2 fibril formation pathway","volume":"16","author":"Lee","year":"2007","journal-title":"Protein Sci."},{"key":"10.1016\/j.jconrel.2025.113641_bb0985","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3389\/fnins.2018.00037","article-title":"Challenges for Alzheimer\u2019s disease therapy: insights from novel mechanisms beyond memory defects","volume":"12","author":"Frozza","year":"2018","journal-title":"Front. Neurosci."},{"issue":"8","key":"10.1016\/j.jconrel.2025.113641_bb0990","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrneurol.2015.119","article-title":"Clearance systems in the brain\u2014implications for Alzheimer disease","volume":"11","author":"Tarasoff-Conway","year":"2015","journal-title":"Nat. Rev. Neurol."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113641_bb0995","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113641_bb1000","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.113691","article-title":"Spatial transcriptomic patterns underlying amyloid-\u03b2 and tau pathology are associated with cognitive dysfunction in Alzheimer\u2019s disease","volume":"43","author":"Yu","year":"2024","journal-title":"Cell Rep."},{"issue":"9","key":"10.1016\/j.jconrel.2025.113641_bb1005","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.3390\/ijms21093272","article-title":"Combination drug therapy for the management of Alzheimer\u2019s disease","volume":"21","author":"Kabir","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113641_bb1010","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7861\/clinmedicine.16-3-247","article-title":"Drug treatments in Alzheimer\u2019s disease","volume":"16","author":"Briggs","year":"2016","journal-title":"Clin. Med."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113641_bb1015","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40265-023-01851-2","article-title":"Lecanemab: first approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.jconrel.2025.113641_bb1020","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J. Prev Alzheimers Dis."},{"issue":"12","key":"10.1016\/j.jconrel.2025.113641_bb1025","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s40265-021-01569-z","article-title":"Aducanumab: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2025.113641_bb1030","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.104823","article-title":"Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials","volume":"139","author":"Petrushina","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jconrel.2025.113641_bb1035","article-title":"RNA therapies for CNS diseases","volume":"115283","author":"Di Francesco","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113641_bb1040","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1021\/acs.chemrev.3c00611","article-title":"Chemically modified platforms for better RNA therapeutics","volume":"124","author":"Shi","year":"2024","journal-title":"Chem. Rev."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113641_bb1045","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3390\/biomedicines9050530","article-title":"Non-immunotherapy application of LNP-mRNA: maximizing efficacy and safety","volume":"9","author":"Vlatkovic","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.jconrel.2025.113641_bb1050","article-title":"Gene editing therapeutics based on mRNA delivery","volume":"115026","author":"Popovitz","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113641_bb1055","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2745\/dds.37.237","article-title":"Lipid nanoparticles for mRNA delivery","volume":"37","author":"Tanaka","year":"2022","journal-title":"Drug Deliv Syst."},{"key":"10.1016\/j.jconrel.2025.113641_bb1060","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.omtn.2021.08.020","article-title":"Advances in mRNA 5-methylcytosine modifications: detection, effectors, biological functions, and clinical relevance","volume":"26","author":"Guo","year":"2021","journal-title":"Mol Ther-Nucleic Acids"},{"issue":"26","key":"10.1016\/j.jconrel.2025.113641_bb1065","doi-asserted-by":"crossref","first-page":"eaaz6893","DOI":"10.1126\/sciadv.aaz6893","article-title":"Impact of mRNA chemistry and manufacturing process on innate immune activation","volume":"6","author":"Nelson","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2025.113641_bb1070","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121645","article-title":"An optimized ionizable cationic lipid for brain tumor-targeted siRNA delivery and glioblastoma immunotherapy","volume":"287","author":"Liu","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.113641_bb1075","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.nantod.2018.10.005","article-title":"mRNA therapeutics deliver a hopeful message","volume":"23","author":"Zhong","year":"2018","journal-title":"Nano Today"},{"key":"10.1016\/j.jconrel.2025.113641_bb1080","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jconrel.2022.03.052","article-title":"Multimeric RNAs for efficient RNA-based therapeutics and vaccines","volume":"345","author":"Kim","year":"2022","journal-title":"J. Control Release Off. J. Control Release Soc."},{"key":"10.1016\/j.jconrel.2025.113641_bb1085","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41434-020-00204-y","article-title":"Self-amplifying RNA vaccines for infectious diseases","volume":"28","author":"Bloom","year":"2021","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2025.113641_bb1090","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/j.ymthe.2022.01.001","article-title":"A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models","volume":"30","author":"Maruggi","year":"2022","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb1095","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1038\/s41467-020-17409-9","article-title":"Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice","volume":"11","author":"McKay","year":"2020","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.jconrel.2025.113641_bb1100","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41434-019-0095-2","article-title":"Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA","volume":"26","author":"Blakney","year":"2019","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2025.113641_bb1105","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jconrel.2021.08.029","article-title":"Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines","volume":"338","author":"Blakney","year":"2021","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2025.113641_bb1110","doi-asserted-by":"crossref","first-page":"588","DOI":"10.7150\/thno.29678","article-title":"Circular RNAs in immune responses and immune diseases","volume":"9","author":"Chen","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2025.113641_bb1115","doi-asserted-by":"crossref","first-page":"1470641","DOI":"10.3389\/fncel.2024.1470641","article-title":"The clinical perspective of circular RNAs in neurodegenerative diseases: potential diagnostic tools and therapeutic targets","volume":"18","author":"Wang","year":"2024","journal-title":"Front. Cell. Neurosci."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113641_bb1120","doi-asserted-by":"crossref","DOI":"10.1111\/cns.14499","article-title":"Regulatory mechanism of circular RNAs in neurodegenerative diseases","volume":"30","author":"Xiao","year":"2023","journal-title":"CNS Neurosci. Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb1125","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1038\/s41467-018-05096-6","article-title":"Engineering circular RNA for potent and stable translation in eukaryotic cells","volume":"9","author":"Wesselhoeft","year":"2018","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113641_bb1130","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.molcel.2019.02.015","article-title":"RNA circularization diminishes immunogenicity and can extend translation duration in vivo","volume":"74","author":"Wesselhoeft","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jconrel.2025.113641_bb1135","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jconrel.2022.05.043","article-title":"Circular RNA: An emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines","volume":"348","author":"Liu","year":"2022","journal-title":"J. Control Release Off. J. Control Release Soc."},{"issue":"30","key":"10.1016\/j.jconrel.2025.113641_bb1140","doi-asserted-by":"crossref","first-page":"eabb4429","DOI":"10.1126\/sciadv.abb4429","article-title":"Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection","volume":"6","author":"Ma","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2025.113641_bb1145","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.brainresbull.2016.04.016","article-title":"Neuropharmacology of N, N-dimethyltryptamine","volume":"126","author":"Carbonaro","year":"2016","journal-title":"Brain Res. Bull."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113641_bb1150","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1021\/acs.molpharmaceut.7b01084","article-title":"In vivo introduction of mRNA encapsulated in lipid nanoparticles to brain neuronal cells and astrocytes via intracerebroventricular administration","volume":"15","author":"Tanaka","year":"2018","journal-title":"Mol. Pharm."},{"issue":"24","key":"10.1016\/j.jconrel.2025.113641_bb1155","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1021\/acs.biochem.3c00371","article-title":"Lipid nanoparticles deliver mRNA to the brain after an intracerebral injection","volume":"62","author":"Tuma","year":"2023","journal-title":"Biochemistry"},{"issue":"8","key":"10.1016\/j.jconrel.2025.113641_bb1160","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/mt.2013.124","article-title":"Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics","volume":"21","author":"Maier","year":"2013","journal-title":"Mol. Ther."},{"issue":"14","key":"10.1016\/j.jconrel.2025.113641_bb1165","doi-asserted-by":"crossref","first-page":"13594","DOI":"10.1021\/acsnano.3c02268","article-title":"Ionizable lipid nanoparticles for therapeutic base editing of congenital brain disease","volume":"17","author":"Palanki","year":"2023","journal-title":"ACS Nano"},{"issue":"11","key":"10.1016\/j.jconrel.2025.113641_bb1170","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/s41551-024-01267-7","article-title":"Optimization of the activity and biodegradability of ionizable lipids for mRNA delivery via directed chemical evolution","volume":"8","author":"Han","year":"2024","journal-title":"Nat. Biomed. Eng."},{"issue":"12","key":"10.1016\/j.jconrel.2025.113641_bb1175","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1039\/D2BM01846B","article-title":"Analysis of PEG-lipid anchor length on lipid nanoparticle pharmacokinetics and activity in a mouse model of traumatic brain injury","volume":"11","author":"Waggoner","year":"2023","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.jconrel.2025.113641_bb1180","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114861","article-title":"Lipid nanoparticle-mediated drug delivery to the brain","volume":"197","author":"Khare","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113641_bb1185","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.molmed.2023.02.004","article-title":"Brain gene therapy with Trojan horse lipid nanoparticles","volume":"29","author":"Pardridge","year":"2023","journal-title":"Trends Mol. Med."},{"issue":"6","key":"10.1016\/j.jconrel.2025.113641_bb1190","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1007\/s13346-023-01482-w","article-title":"ApoE\u2014functionalization of nanoparticles for targeted brain delivery\u2014a feasible method for polyplexes?","volume":"14","author":"Hartl","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2025.113641_bb1195","doi-asserted-by":"crossref","first-page":"104619","DOI":"10.1016\/j.nbd.2019.104619","article-title":"Optimizing intracellular antibodies (intrabodies\/nanobodies) to treat neurodegenerative disorders","volume":"134","author":"Messer","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jconrel.2025.113641_bb1200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2016.09.019","article-title":"Camelid single-domain antibodies: a versatile tool for in vivo imaging of extracellular and intracellular brain targets","volume":"243","author":"Li","year":"2016","journal-title":"J. Control Release Off. J. Control Release Soc."},{"key":"10.1016\/j.jconrel.2025.113641_bb1205","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41531-018-0062-4","article-title":"Proteasome-targeted nanobodies alleviate pathology and functional decline in an \u03b1-synuclein-based Parkinson\u2019s disease model","volume":"4","author":"Chatterjee","year":"2018","journal-title":"NPJ Park Dis"},{"key":"10.1016\/j.jconrel.2025.113641_bb1210","first-page":"rs","article-title":"Targeting soluble amyloid-Beta oligomers with a novel Nanobody","author":"Haynes","year":"2024","journal-title":"Res Sq."},{"key":"10.1016\/j.jconrel.2025.113641_bb1215","doi-asserted-by":"crossref","first-page":"1236810","DOI":"10.3389\/fnano.2023.1236810","article-title":"Combining metal nanoparticles and nanobodies to boost the biomedical imaging in neurodegenerative diseases","volume":"5","author":"Sanna","year":"2023","journal-title":"Front Nanotechnol."},{"issue":"7","key":"10.1016\/j.jconrel.2025.113641_bb1220","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1039\/D3NA00699A","article-title":"Ionic liquid-coated lipid nanoparticles increase siRNA uptake into CNS targets","volume":"6","author":"Khare","year":"2024","journal-title":"Nanoscale Adv."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113641_bb1225","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.jconrel.2025.113641_bb1230","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.3390\/nu11102265","article-title":"Functional expression of choline transporters in the blood\u2013brain barrier","volume":"11","author":"Inazu","year":"2019","journal-title":"Nutrients"},{"issue":"13","key":"10.1016\/j.jconrel.2025.113641_bb1235","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/S0024-3205(03)00504-6","article-title":"The blood-brain barrier choline transporter as a brain drug delivery vector","volume":"73","author":"Allen","year":"2003","journal-title":"Life Sci."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113641_bb1240","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/scientificamerican1078-62","article-title":"Brain function and blood flow","volume":"239","author":"Lassen","year":"1978","journal-title":"Sci. Am."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113641_bb1245","doi-asserted-by":"crossref","first-page":"1801419","DOI":"10.1002\/adhm.201801419","article-title":"Engineering immune tolerance with biomaterials","volume":"8","author":"Gammon","year":"2019","journal-title":"Adv. Healthc. Mater."},{"issue":"6","key":"10.1016\/j.jconrel.2025.113641_bb1250","doi-asserted-by":"crossref","first-page":"2202238","DOI":"10.1002\/adhm.202202238","article-title":"Tissue-targeted drug delivery strategies to promote antigen-specific immune tolerance","volume":"12","author":"Rui","year":"2023","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2025.113641_bb1255","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jconrel.2019.01.015","article-title":"Dexamethasone palmitate nanoparticles: An efficient treatment for rheumatoid arthritis","volume":"296","author":"Lorscheider","year":"2019","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb1260","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11095-022-03433-5","article-title":"CNS delivery of nucleic acid therapeutics: beyond the blood\u2013brain barrier and towards specific cellular targeting","volume":"40","author":"D\u2019Souza","year":"2023","journal-title":"Pharm. Res."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113641_bb1265","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.molmed.2023.12.006","article-title":"Focused ultrasound gene delivery for the treatment of neurological disorders","volume":"30","author":"Kofoed","year":"2024","journal-title":"Trends Mol. Med."},{"issue":"7","key":"10.1016\/j.jconrel.2025.113641_bb1270","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/jcbfm.2014.71","article-title":"The size of blood\u2013brain barrier opening induced by focused ultrasound is dictated by the acoustic pressure","volume":"34","author":"Chen","year":"2014","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.jconrel.2025.113641_bb1275","doi-asserted-by":"crossref","unstructured":"JP BI, Silva G. Targeting the brain: advances in drug delivery. Curr. Pharm. Biotechnol. 2012;13(12):2417\u201326.","DOI":"10.2174\/138920112803341833"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb1280","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/02656736.2018.1514468","article-title":"Microbubble-assisted MRI-guided focused ultrasound for hyperthermia at reduced power levels","volume":"35","author":"Santos","year":"2018","journal-title":"Int. J. Hyperth."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb1285","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ncl.2013.07.008","article-title":"Magnetic resonance guided focused ultrasound: a new technology for clinical neurosciences","volume":"32","author":"Jolesz","year":"2013","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.jconrel.2025.113641_bb1290","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jconrel.2015.08.059","article-title":"Drug and gene delivery across the blood\u2013brain barrier with focused ultrasound","volume":"219","author":"Timbie","year":"2015","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.jconrel.2025.113641_bb1295","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1006\/bbrc.2002.6495","article-title":"Synergistic effect of cold mannitol and Na+\/Ca2+ exchange blocker on blood\u2013brain barrier opening","volume":"291","author":"Ikeda","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"16","key":"10.1016\/j.jconrel.2025.113641_bb1300","doi-asserted-by":"crossref","first-page":"2101090","DOI":"10.1002\/advs.202101090","article-title":"Development of novel therapeutics targeting the blood\u2013brain barrier: from barrier to carrier","volume":"8","author":"Li","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jconrel.2025.113641_bb1305","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jconrel.2021.01.027","article-title":"Minimally invasive nasal depot (MIND) technique for direct BDNF AntagoNAT delivery to the brain","volume":"331","author":"Padmakumar","year":"2021","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.jconrel.2025.113641_bb1310","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3390\/pharmaceutics13040492","article-title":"Delivery of therapeutic agents to the central nervous system and the promise of extracellular vesicles","volume":"13","author":"Ren\u00e9","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.113641_bb1315","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.addr.2020.02.006","article-title":"Intrathecal drug delivery in the era of nanomedicine","volume":"165","author":"Fowler","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.113641_bb1320","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.addr.2014.01.008","article-title":"Ultrasound-mediated blood\u2013brain barrier disruption for targeted drug delivery in the central nervous system","volume":"72","author":"Aryal","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113641_bb1325","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/jps.21924","article-title":"Intranasal delivery to the central nervous system: mechanisms and experimental considerations","volume":"99","author":"Dhuria","year":"2010","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb1330","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","article-title":"Antisense oligonucleotides: the next frontier for treatment of neurological disorders","volume":"14","author":"Rinaldi","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113641_bb1335","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","article-title":"Strategies for delivering therapeutics across the blood\u2013brain barrier","volume":"20","author":"Terstappen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.jconrel.2025.113641_bb1340","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/14712598.2024.2386339","article-title":"Intraparenchymal delivery of adeno-associated virus vectors for the gene therapy of neurological diseases","volume":"24","author":"Kumagai","year":"2024","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb1345","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/pharmaceutics16010066","article-title":"Nose-to-brain (N2B) delivery: An alternative route for the delivery of biologics in the management and treatment of central nervous system disorders","volume":"16","author":"Patharapankal","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.113641_bb1350","first-page":"1","article-title":"Using nanotechnology to deliver biomolecules from nose to brain\u2014peptides, proteins, monoclonal antibodies and RNA. Drug Deliv","author":"Borrajo","year":"2022","journal-title":"Transl. Res."},{"issue":"12","key":"10.1016\/j.jconrel.2025.113641_bb1355","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.3390\/pharmaceutics12121134","article-title":"Bypassing the blood\u2013brain barrier: direct intracranial drug delivery in epilepsies","volume":"12","author":"Gernert","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.113641_bb1360","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.omto.2021.12.010","article-title":"Intracranial delivery of synthetic mRNA to suppress glioblastoma","volume":"24","author":"Peng","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"issue":"22","key":"10.1016\/j.jconrel.2025.113641_bb1365","doi-asserted-by":"crossref","first-page":"12284","DOI":"10.3390\/ijms252212284","article-title":"Recent advances and prospects in RNA drug development","volume":"25","author":"Tani","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113641_bb1370","doi-asserted-by":"crossref","first-page":"102313","DOI":"10.1016\/j.omtn.2024.102313","article-title":"Advancements and challenges in mRNA and ribonucleoprotein-based therapies: from delivery systems to clinical applications","volume":"35","author":"Eftekhari","year":"2024","journal-title":"Mol Ther-Nucleic"},{"key":"10.1016\/j.jconrel.2025.113641_bb1375","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.trsl.2021.11.009","article-title":"Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials","volume":"242","author":"Whitley","year":"2022","journal-title":"Transl. Res."},{"issue":"10","key":"10.1016\/j.jconrel.2025.113641_bb1380","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jconrel.2025.113641_bb1385","series-title":"Global Early Access Program to Provide Tofersen to Patients with Amyotrophic Lateral Sclerosis (ALS) Associated with a Mutation in the Superoxide Dismutase 1 (SOD1) Gene","author":"Biogen","year":"2024"},{"key":"10.1016\/j.jconrel.2025.113641_bb1390","series-title":"A Phase 3 Randomized, Placebo-Controlled Trial with a Longitudinal Natural History Run-In and Open-Label Extension to Evaluate BIIB067 Initiated in Clinically Presymptomatic Adults with a Confirmed Superoxide Dismutase 1 Mutation","author":"Biogen","year":"2024"},{"issue":"2","key":"10.1016\/j.jconrel.2025.113641_bb1395","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40259-022-00519-9","article-title":"Antisense oligonucleotide therapy: from design to the Huntington disease clinic","volume":"36","author":"Rook","year":"2022","journal-title":"BioDrugs"},{"issue":"7","key":"10.1016\/j.jconrel.2025.113641_bb1400","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/nm.2834","article-title":"Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects","volume":"18","author":"Jimenez-Mateos","year":"2012","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.jconrel.2025.113641_bb1405","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.molmed.2021.03.010","article-title":"Adeno-associated virus vector for central nervous system gene therapy","volume":"27","author":"Zhu","year":"2021","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.jconrel.2025.113641_bb1410","doi-asserted-by":"crossref","unstructured":"Bors LA, Erd\\Ho F. Overcoming the blood\u2013brain barrier. Challenges and tricks for CNS drug delivery. Sci. Pharm. 2019;87(1):6.","DOI":"10.3390\/scipharm87010006"},{"key":"10.1016\/j.jconrel.2025.113641_bb1415","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s11095-007-9324-2","article-title":"Drug targeting to the brain","volume":"24","author":"Pardridge","year":"2007","journal-title":"Pharm. Res."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113641_bb1420","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1046\/j.1471-4159.1998.70051781.x","article-title":"CNS drug design based on principles of blood-brain barrier transport","volume":"70","author":"Pardridge","year":"1998","journal-title":"J. Neurochem."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113641_bb1425","doi-asserted-by":"crossref","first-page":"101","DOI":"10.18609\/nai.2024.015","article-title":"Challenges and advances of the stability of mRNA delivery therapeutics","volume":"1","author":"Zhai","year":"2024","journal-title":"Nucleic Acid Insights."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113641_bb1430","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1586\/14760584.2015.986104","article-title":"Lipid-based mRNA vaccine delivery systems","volume":"14","author":"Midoux","year":"2015","journal-title":"Expert Rev. Vaccines"},{"issue":"18","key":"10.1016\/j.jconrel.2025.113641_bb1435","doi-asserted-by":"crossref","first-page":"10604","DOI":"10.1093\/nar\/gkab764","article-title":"Theoretical basis for stabilizing messenger RNA through secondary structure design","volume":"49","author":"Wayment-Steele","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2025.113641_bb1440","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114041","article-title":"Modulating intracellular pathways to improve non-viral delivery of RNA therapeutics","volume":"181","author":"Van de Vyver","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"39","key":"10.1016\/j.jconrel.2025.113641_bb1445","doi-asserted-by":"crossref","first-page":"2404510","DOI":"10.1002\/adfm.202404510","article-title":"Beyond the endosomal bottleneck: understanding the efficiency of mRNA\/LNP delivery","volume":"34","author":"Liu","year":"2024","journal-title":"Adv. Funct. Mater."},{"issue":"20","key":"10.1016\/j.jconrel.2025.113641_bb1450","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1021\/acs.accounts.3c00442","article-title":"Chemical modifications of mRNA ends for therapeutic applications","volume":"56","author":"Warminski","year":"2023","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.jconrel.2025.113641_bb1455","article-title":"The Immunostimulatory nature of mRNA lipid nanoparticles","volume":"115175\u2013115175","author":"Sharma","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.113641_bb1460","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jconrel.2024.08.030","article-title":"Enhancing RNA-lipid nanoparticle delivery: organ-and cell-specificity and barcoding strategies","volume":"375","author":"Wei","year":"2024","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb1465","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s42003-024-06235-0","article-title":"Overcoming thermostability challenges in mRNA\u2013lipid nanoparticle systems with piperidine-based ionizable lipids","volume":"7","author":"Hashiba","year":"2024","journal-title":"Commun Biol."},{"key":"10.1016\/j.jconrel.2025.113641_bb1470","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jconrel.2024.07.052","article-title":"Physicochemical and structural insights into lyophilized mRNA-LNP from lyoprotectant and buffer screenings","volume":"373","author":"Fan","year":"2024","journal-title":"J. Control. Release"},{"issue":"22","key":"10.1016\/j.jconrel.2025.113641_bb1475","doi-asserted-by":"crossref","first-page":"13983","DOI":"10.1021\/acsnano.4c00182","article-title":"Mechanisms and barriers in nanomedicine: Progress in the field and future directions","volume":"18","author":"Anchordoquy","year":"2024","journal-title":"ACS Nano"},{"issue":"11","key":"10.1016\/j.jconrel.2025.113641_bb1480","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/s41565-024-01754-7","article-title":"A translational framework to DELIVER nanomedicines to the clinic","volume":"19","author":"Joyce","year":"2024","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2025.113641_bb1485","article-title":"Artificial intelligence-guided design of lipid nanoparticles for pulmonary gene therapy","volume":"1\u201310","author":"Witten","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2025.113641_bb1490","unstructured":"Xu L, Li C, Liao R, Xiao Q, Wang X, Zhao Z, et al. From sequence to system: enhancing IVT mRNA vaccine effectiveness through cutting-edge technologies. Mol. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb1495","doi-asserted-by":"crossref","first-page":"10804","DOI":"10.1038\/s41467-024-55072-6","article-title":"Artificial intelligence-driven rational design of ionizable lipids for mRNA delivery","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.113641_bb1500","doi-asserted-by":"crossref","first-page":"102991","DOI":"10.1016\/j.sbi.2025.102991","article-title":"Deep learning for RNA structure prediction","volume":"91","author":"Wang","year":"2025","journal-title":"Curr. Opin. Struct. Biol."},{"issue":"7978","key":"10.1016\/j.jconrel.2025.113641_bb1505","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41586-023-06127-z","article-title":"Algorithm for optimized mRNA design improves stability and immunogenicity","volume":"621","author":"Zhang","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2025.113641_bb1510","doi-asserted-by":"crossref","first-page":"143152","DOI":"10.1016\/j.cej.2023.143152","article-title":"Engineering brain-derived neurotrophic factor mRNA delivery for the treatment of Alzheimer\u2019s disease","volume":"466","author":"Li","year":"2023","journal-title":"Chem. Engl. J."},{"key":"10.1016\/j.jconrel.2025.113641_bb1515","article-title":"Rational Design of Lipid Nanoparticles for enhanced mRNA vaccine delivery via machine learning","volume":"2405618","author":"Bae","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2025.113641_bb1520","series-title":"AGILE Platform: A Deep Learning-Powered Approach to Accelerate LNP Development for mRNA Delivery","author":"Xu","year":"2023"},{"key":"10.1016\/j.jconrel.2025.113641_bb1525","article-title":"Accelerating ionizable lipid discovery for mRNA delivery using machine learning and combinatorial chemistry","volume":"1\u20137","author":"Li","year":"2024","journal-title":"Nat. Mater."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113641_bb1530","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1021\/acs.nanolett.3c03509","article-title":"Predictive high-throughput platform for dual screening of mrna lipid nanoparticle blood\u2013brain barrier transfection and crossing","volume":"24","author":"Han","year":"2024","journal-title":"Nano Lett"},{"key":"10.1016\/j.jconrel.2025.113641_bb1535","article-title":"Biologics, theranostics, and personalized medicine in drug delivery systems","volume":"107086","author":"Puccetti","year":"2024","journal-title":"Pharmacol. Res."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113641_bb1540","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1039\/D1NR06858J","article-title":"Development of a high-throughput platform for screening lipid nanoparticles for mRNA delivery","volume":"14","author":"Cui","year":"2022","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2025.113641_bb1545","doi-asserted-by":"crossref","first-page":"102081","DOI":"10.1016\/j.artmed.2021.102081","article-title":"Artificial intelligence in neurodegenerative diseases: a review of available tools with a focus on machine learning techniques","volume":"117","author":"T\u0103u\u0163an","year":"2021","journal-title":"Artif. Intell. Med."},{"key":"10.1016\/j.jconrel.2025.113641_bb1550","series-title":"AI and Neuro-Degenerative Diseases: Insights and Solutions","first-page":"1","article-title":"Demystifying the role of artificial intelligence in neurodegenerative diseases","author":"Mathur","year":"2024"},{"key":"10.1016\/j.jconrel.2025.113641_bb1555","first-page":"648","article-title":"Applications of artificial intelligence to diagnosis of neurodegenerative diseases","volume":"308","author":"Feng","year":"2023","journal-title":"Stud. Health Technol. Inform."},{"key":"10.1016\/j.jconrel.2025.113641_bb1560","first-page":"17","article-title":"Application of gene editing in neurodegenerative diseases, volume II","author":"Qi","year":"2023","journal-title":"Front. Neurosci."},{"issue":"6","key":"10.1016\/j.jconrel.2025.113641_bb1565","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.3390\/pharmaceutics14061252","article-title":"CRISPR-Cas9-based technology and its relevance to gene editing in Parkinson\u2019s disease","volume":"14","author":"Rahman","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.113641_bb1570","doi-asserted-by":"crossref","first-page":"115359","DOI":"10.1016\/j.addr.2024.115359","article-title":"Delivery of nucleic acid based genome editing platforms via lipid nanoparticles: Clinical applications","author":"Masarwy","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.113641_bb1575","doi-asserted-by":"crossref","DOI":"10.3389\/fgeed.2021.644319","article-title":"Delivery platforms for CRISPR\/Cas9 genome editing of glial cells in the central nervous system","volume":"3","author":"Meneghini","year":"2021","journal-title":"Front Genome Ed."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113641_bb1580","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1208\/s12248-023-00833-2","article-title":"Lipid nanoparticle-enabled intracellular delivery of prime editors","volume":"25","author":"Herrera-Barrera","year":"2023","journal-title":"AAPS J."},{"issue":"6","key":"10.1016\/j.jconrel.2025.113641_bb1585","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3390\/ph17060763","article-title":"Emerging perspectives on prime editor delivery to the brain","volume":"17","author":"BenDavid","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jconrel.2025.113641_bb1590","doi-asserted-by":"crossref","first-page":"1304110","DOI":"10.3389\/fgeed.2024.1304110","article-title":"Epigenetic editing for autosomal dominant neurological disorders","volume":"6","author":"Waldo","year":"2024","journal-title":"Front Genome Ed."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113641_bb1595","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.3390\/cimb46050255","article-title":"Recent therapeutic gene editing applications to genetic disorders","volume":"46","author":"Deneault","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb1600","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/s12951-024-02630-1","article-title":"Steering the course of CAR T cell therapy with lipid nanoparticles","volume":"22","author":"Khawar","year":"2024","journal-title":"J Nanobiotechnology."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113641_bb1605","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/brain\/awae362","article-title":"Current state and perspectives of CAR T cell therapy in central nervous system diseases","volume":"148","author":"Pfeffer","year":"2025","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113641_bb1610","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s40364-024-00679-6","article-title":"Advances in CAR-T therapy for central nervous system tumors","volume":"12","author":"Zhou","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.jconrel.2025.113641_bb1615","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103350","article-title":"Advances in chimeric antigen receptor T cell therapy for autoimmune and autoinflammatory diseases and their complications","volume":"150","author":"Zeng","year":"2025","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jconrel.2025.113641_bb1620","doi-asserted-by":"crossref","unstructured":"Fischbach, Felix, Johanna Richter, Lena Kristina Pfeffer, Boris Fehse, Susanna Carolina Berger, Stefanie Reinhardt, Jens Kuhle et al. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med 5 (6) (2024) 550-558.","DOI":"10.1016\/j.medj.2024.03.002"},{"issue":"6295","key":"10.1016\/j.jconrel.2025.113641_bb1625","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.jconrel.2025.113641_bb1630","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2025.113641_bb1635","unstructured":"Brittain G, Roldan E, Alexander T, Saccardi R, Snowden JA, Sharrack B, et al. The role of chimeric antigen receptor T-cell therapy in immune-mediated neurological diseases. Ann. Neurol."},{"key":"10.1016\/j.jconrel.2025.113641_bb1640","first-page":"31","article-title":"Lipid nanoparticles outperform electroporation in mRNA-based CAR T cell engineering","author":"Kitte","year":"2023","journal-title":"Mol. Ther. Methods Clin Dev."},{"issue":"11","key":"10.1016\/j.jconrel.2025.113641_bb1645","doi-asserted-by":"crossref","first-page":"2304378","DOI":"10.1002\/smll.202304378","article-title":"In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism","volume":"20","author":"Billingsley","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2025.113641_bb1650","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2024.102518","article-title":"In situ engineering of mRNA-CAR T cells using spleen-targeted ionizable lipid nanoparticles to eliminate cancer cells","volume":"59","author":"Li","year":"2024","journal-title":"Nano Today"},{"issue":"12","key":"10.1016\/j.jconrel.2025.113641_bb1655","doi-asserted-by":"crossref","first-page":"2206187","DOI":"10.1002\/advs.202206187","article-title":"Lipid nanoparticles deliver the therapeutic VEGFA mRNA in vitro and in vivo and transform extracellular vesicles for their functional extensions","volume":"10","author":"Nawaz","year":"2023","journal-title":"Adv. Sci."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113641_bb1660","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1007\/s00415-020-10237-3","article-title":"Neurological updates: neurological complications of CAR-T therapy","volume":"268","author":"Tallantyre","year":"2020","journal-title":"J. Neurol."},{"issue":"12","key":"10.1016\/j.jconrel.2025.113641_bb1665","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2025.113641_bb1670","first-page":"14","article-title":"CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: is it still a concern?","author":"Velasco","year":"2023","journal-title":"Front. Neurol."},{"issue":"11","key":"10.1016\/j.jconrel.2025.113641_bb1675","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1016\/j.ymthe.2024.09.019","article-title":"Synergistic integration of mRNA-LNP with CAR-engineered immune cells: pioneering progress in immunotherapy","volume":"32","author":"Chen","year":"2024","journal-title":"Mol. Ther."},{"issue":"8","key":"10.1016\/j.jconrel.2025.113641_bb1680","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.apsb.2020.01.015","article-title":"Gene therapy for neurodegenerative disorders: advances, insights and prospects","volume":"10","author":"Chen","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"issue":"15","key":"10.1016\/j.jconrel.2025.113641_bb1685","doi-asserted-by":"crossref","first-page":"13217","DOI":"10.1021\/acs.jmedchem.4c01176","article-title":"Synthesis of Lipidated ligands and formulation of glia-specific LNPs for RNAi-mediated BBB protection","volume":"67","author":"Xiao","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2025.113641_bb1690","first-page":"34","article-title":"Astrocyte-targeted siRNA delivery by adenosine-functionalized LNP in mouse TBI model","author":"Xiao","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"10","key":"10.1016\/j.jconrel.2025.113641_bb1695","doi-asserted-by":"crossref","first-page":"9126","DOI":"10.1007\/s12274-024-6827-7","article-title":"Lipid nanoparticles deliver mRNA to the blood\u2013brain barrier","volume":"17","author":"Kuzminich","year":"2024","journal-title":"Nano Res."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925002615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925002615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T01:57:42Z","timestamp":1769219862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925002615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":339,"alternative-id":["S0168365925002615"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113641","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid nanoparticle (LNP) mediated mRNA delivery in neurodegenerative diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113641","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113641"}}